AbbVie Says Health Canada Issues Notice Of Compliance For RINVOQ For Treatment Of Adults With GCA, Both Used In Combination With Tapering Course Of Corticosteroids And As Monotherapy Following Discontinuation Of Corticosteroids

AbbVie, Inc. +2.05%

AbbVie, Inc.

ABBV

217.49

+2.05%

  • RINVOQ is the first and only oral advanced therapy approved for the treatment of giant cell arteritis (GCA) in Canadian adults1
  • GCA is the most common vasculitis in Canada, primarily affecting adults over 502
  • This marks the eighth approved indication for RINVOQ in Canada across rheumatology, gastroenterology and dermatology3

MONTREAL, Aug. 27, 2025 /CNW/ - AbbVie today announced that Health Canada has issued a Notice of Compliance for RINVOQ® (upadacitinib) for the treatment of adults with giant cell arteritis (GCA), both used in combination with a tapering course of corticosteroids and as monotherapy following discontinuation of corticosteroids.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.